Jeffrey Jones to Disease-Free Survival
This is a "connection" page, showing publications Jeffrey Jones has written about Disease-Free Survival.
Connection Strength
0.159
-
Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol. 2018 01; 19(1):65-75.
Score: 0.139
-
Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. J Clin Oncol. 2009 Dec 10; 27(35):6012-8.
Score: 0.020